0OO9.L - Fresenius SE & Co. KGaA
| Previous close | 27.70 |
| Open | 27.38 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 26.72 - 27.38 |
| 52-week range | 26.72 - 27.38 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Fresenius SE & Co. KGaA: Outlook 2023 – Fresenius advances with deconsolidation of Fresenius Medical Care by changing its legal form into a German stock corporation (Aktiengesellschaft)
Fresenius SE & Co. KGaA / Key word(s): Forecast/Strategic Company DecisionFresenius SE & Co. KGaA: Outlook 2023 – Fresenius advances with deconsolidation of Fresenius Medical Care by changing its legal form into a German stock corporation (Aktiengesellschaft)21-Feb-2023 / 19:02 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcem
- EQS Group
Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation
Fresenius SE & Co. KGaA / Key word(s): MiscellaneousFresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation 09-Feb-2023 / 16:24 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.As part of the „strategic review” initi
- EQS Group
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
Fresenius SE & Co. KGaA / Key word(s): PersonnelHelen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company05-Dec-2022 / 23:40 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the companyToday, the Supervisory Board of
- EQS Group
Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
Fresenius SE & Co. KGaA / Key word(s): Change in ForecastChallenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised30-Oct-2022 / 17:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Fresenius SE & Co. KGaA: Challenging macroeco
- EQS Group
Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius
Fresenius SE & Co. KGaA / Key word(s): PersonnelFresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius19-Aug-2022 / 18:33 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Michael Sen to succeed Stephan Sturm as CEO of FreseniusMichael Sen (53) will become Chief Executive Officer of Fresenius on Octob
ReutersFresenius Medical shares at 12-year low as labour costs weigh on profit
(Reuters) -Shares in the world's largest kidney dialysis provider Fresenius Medical Care (FMC) plunged more than 12% to a 12-year low on Thursday after it cut its earnings outlook as costs surge and a U.S. staff shortage leaves it scrambling for nurses. In an unscheduled statement late on Wednesday, FMC flagged a decline in net income approaching 20% this year and withdrew its 2025 targets. Most of its U.S. patients are covered by state-run insurer Medicare, with lump-sum reimbursements per patient that only get adjusted to cost inflation with a two-year delay, the chief executive of FMC parent Fresenius, Stephan Sturm, said on an analyst call.
- EQS Group
Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised
Fresenius SE & Co. KGaA / Key word(s): Change in ForecastFresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised 27-Jul-2022 / 22:45 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Fresenius SE & Co. KGaA: Significant
ZacksAfter Plunging 11.8% in 4 Weeks, Here's Why the Trend Might Reverse for Fresenius (FMS)
The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BloombergMusk’s About-Face on Twitter Sends Takeover Saga to Delaware
(Bloomberg) -- Now that Elon Musk has decided that he doesn’t want to buy Twitter Inc. after all, he can’t just walk away from the $44 billion contract. The billionaire co-founder of Tesla Inc. will need to make his case before a judge in Delaware that Twitter failed to uphold its side of a merger deal reached in April. If history is a guide, his job won’t be easy.Most Read from BloombergIvana Trump, First Wife of Former President, Dies At 73Chinese Homebuyers Across 22 Cities Refuse to Pay Mort
BloombergMusk Effort to Void Twitter Buyout Sets Up Delaware Court Fight
(Bloomberg) -- Elon Musk’s move to dump his $44 billion deal for Twitter Inc. sets the stage for a titanic legal battle in a Delaware court that typically frowns on efforts to back out of merger agreements.Most Read from BloombergFresh US Inflation Peak to Keep Fed on Aggressive Rate PathElon’s OutJan. 6 Panel Maps Path From ‘Wild’ Trump Tweet to Capitol AttackNYC Prepares for the ‘Big One’ With Nuclear Attack PSA VideoMillions of Americans Regret the Great ResignationMinutes after Musk disclose